Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

Intensity Therapeutics is seeking collaboration partnerships


Intensity Therapeutics is a clinical development stage company that is conducting human clinical testing of its lead product INT230-6 in refractory solid tumor cancers. The Company is interested in collaborating with pharmaceutical, imaging or biotechnology companies.  In particular the Company would like to test combinations of its novel drug with products that may be synergistic.  Data reported by Intensity Therapeutics have shown INT230-6 is synergistic with anti-PD-1 compounds. 

 

 

Please contact Lew Bender via email at lbender@intensitytherapeutics.com or call our office at (203) 221-7377.

Contact Us


Intensity Therapeutics, Inc.
61 Wilton Road, 3rd Floor
Westport, CT 06880


Tel. (203) 221-7377
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Click here for career inquiries

Who we are


Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News

Case number 01930099